观点：APOBEC 诱变在 HIV 和癌症进化中的耐药性和免疫逃逸。
Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution.
机构信息
CRUK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK; Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London, UK.
CRUK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK.
出版信息
Ann Oncol. 2018 Mar 1;29(3):563-572. doi: 10.1093/annonc/mdy003.
The apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) mutational signature has only recently been detected in a multitude of cancers through next-generation sequencing. In contrast, APOBEC has been a focus of virology research for over a decade. Many lessons learnt regarding APOBEC within virology are likely to be applicable to cancer. In this review, we explore the parallels between the role of APOBEC enzymes in HIV and cancer evolution. We discuss data supporting the role of APOBEC mutagenesis in creating HIV genome heterogeneity, drug resistance, and immune escape variants. We hypothesize similar functions of APOBEC will also hold true in cancer.
载脂蛋白 B mRNA 编辑酶、催化多肽样（APOBEC）突变特征最近才通过下一代测序在多种癌症中被检测到。相比之下，APOBEC 一直是病毒学研究的焦点已有十多年了。在病毒学中获得的许多关于 APOBEC 的经验教训可能适用于癌症。在这篇综述中，我们探讨了 APOBEC 酶在 HIV 和癌症进化中的作用的相似之处。我们讨论了支持 APOBEC 突变在产生 HIV 基因组异质性、耐药性和免疫逃逸变体中的作用的数据。我们假设 APOBEC 的类似功能也将在癌症中成立。
Zotero 插件